News
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Mar 3, 2021
(OTC-CELZ) Creative Medical Technology Holdings announced today that due to COVID related technical changes in the FDA's submission requirements, the Company's ImmCelz® Investigational New Drug...
-
Feb 16, 2021Company Aims to Leverage Immune Modulatory Technology to Alleviate Need for Immune Suppressants after Transplantation
(OTC – CELZ) Creative Medical Technology Holdings, Inc. announced today filing of a patent application covering the use of ImmCelz® regenerative cell therapy for preventing rejection of...
-
Feb 10, 2021Company Advances Towards Clinical Trial to Address Premature Ovarian Failure Patients
(OTC-CELZ) Creative Medical Technology Holdings announced today new data explaining mechanisms of action of its patented OvaStem® female infertility/ovarian failure treatment. OvaStem®, which is...
-
Feb 8, 2021Clinical Stage Regenerative Medicine Company Plans to Develop Clinical Programs for Major Uses of ImmCelz® Regenerative Immunotherapy
(OTC-CELZ) Creative Medical Technology Holdings Inc. announced today recruitment of Dr. Caigan Du, Associate Professor at the University of British Columbia to the Company's Scientific Advisory Board.
-
Feb 1, 2021Company Demonstrates that in Addition to Activating Endogenous Stem Cells and T Regulatory Cells ImmCelz® Induces Surge of Therapeutic Protein HGF-1
(OTC – CELZ) Creative Medical Technology Holdings, Inc. announced today new data demonstrating that administration of ImmCelz® to animals with a variety of conditions results is a significant...